HDL-cholesterol: is it really good? Differences between apoA-I and HDL

Area of Science:

• Cardiovascular Science
• Metabolic Research
• Pharmacology

Background:

• High-density lipoprotein cholesterol (HDL-C) has been recognized for its protective role in atherosclerosis.
• Despite statin therapy effectively lowering low-density lipoprotein cholesterol (LDL-C), residual cardiovascular disease (CVD) risk persists.
• Low HDL-C levels are an independent risk factor for CVD, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the pathways involved in HDL-C metabolism.
• To discuss emerging pharmacological approaches targeting HDL-C.
• To provide perspective on HDL-C's role in atherosclerosis, considering recent trial outcomes.

Main Methods:

• Review of existing literature on HDL-C metabolism and function.
• Analysis of clinical trial data, including the ILLUMINATE trial outcomes.
• Exploration of novel drug targets and mechanisms related to HDL-C.

Main Results:

• The protective role of HDL-C in atherosclerosis is complex and not fully elucidated.
• The failure of torcetrapib highlights the challenges in targeting HDL-C for cardiovascular benefit.
• Statins reduce cardiovascular risk, but a significant residual risk remains.

Conclusions:

• Further research into HDL-C pathways is crucial for developing effective therapies.
• New pharmacological strategies targeting HDL-C metabolism are under investigation.
• Addressing residual risk in cardiovascular disease may involve modulating HDL-C.